Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo. He is joined by Chief Financial Officer, Ed Stelmakh; President, Steve Silvestro; General Counsel, Marion Odense Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva. At the conclusion of today's earnings call, I will provide some important cautions regarding the forward-looking statements made by management during today's call. I would like to remind everyone that today's call is being recorded and will be made available for replay via webcast only. Instructions are included in today's press release and in the Investors section of the company's website. Now I would like to turn the call over to OptimizeRx's CEO, William Febbo. Sir, please go ahead.

Thank you, operator, and good afternoon to everyone joining today's first quarter 2024 earnings call. I'm delighted to share today's results, which came in ahead of our April 26 preliminary unaudited earnings announcement. Momentum from Q4 2023 has continued into 2024, with Q1 revenues increasing 51% year-over-year to $19.7 million, which topped the high end of our preannounced revenue range. Growth is being driven by favorable competitive dynamics. We are seeing stronger customer engagement as pharma is looking for partners with integrated precision offerings that have true scalability in terms of HCP and DTC reach, interoperability across multiple points of care, and the capability to accurately report insights back in a timely manner. The tailwinds are welcome as we continue to lead with our clients around a more efficient and precise platform for marketing and health care. We are in the right place at the right time. Our year-over-year top line strength was driven by a clear demand for our Dynamic Audience Activation Platform, or DAAP, as well as from our Medicx Health acquisition. Our thesis that smarter solutions, such as DAAP, will gain market share is continuing to be validated, and I believe we have significant upside potential from cross-selling between the HCP and DTC customer bases. Recall, at the time of the acquisition, we only had about 20% customer base overlap among the 300-plus brands on the platform. Therefore, it should not be a surprise that the in-year pipeline is building at an unprecedented rate in our history as a company. This momentum, as well as financial and operational continuity from Q4 of last year, has carried over to the first quarter of 2024. We are optimistic on this year, and we are off to a strong start, having signed 9 DAAP deals in the quarter, building on the 24 deals we signed in '23. While we are maintaining our guidance, which calls for revenue to reach a minimum of $100 million for 2024 with an adjusted EBITDA of at least $11 million for the year, we will continue to watch our visibility and fine-tune the numbers as appropriate. Our continued growth would not be possible without our market-leading team that strives to excel and surpass expectations every day. I want to thank everyone on the OptimizeRx team for their concerted effort to navigate through a very complex dynamic yet still nascent digital pharma marketing landscape that the industry is adopting. The OptimizeRx platform and solutions will fundamentally reshape the dynamics of marketing engagement among pharma, patients, and prescribers. And our mission-driven culture will attract, retain and enhance all the relationships a technology company needs to be a reliable partner. With that, I'll turn it over to the company President, Steve Silvestro, to give more color on DAAP as well as other commercial updates. Steve?

Thanks, Will. As a reminder, our Dynamic Audience Activation Platform is, in essence, an AI-powered patient and HCP finder for pharma brands that we serve. Simply put, DAAP algorithms work by searching through the sea of existing patient-level data to find brand-eligible patients. Once found, DAAP determines the best means of communication with that patient. A call-to-action message can then be triggered and sent to the appropriate doctor or patient at the most opportune time. This process is recurring as the algorithms learn over time, improving execution. Leveraging this technology enables OPRX to move past our peer group's spray-and-pray messaging commonly found in the space and instead deliver the appropriate information to the correct person when it's most relevant and likely to drive script lift. In doing so, we're helping to build deeper relationships among pharma brands, doctors, and patients falling in line with industry trends as pharma is looking to partner with scalable platforms that have agile precision marketing capabilities, which all falls in line with the core of what DAAP enables. With that said, we've had a very promising start to 2024. The company is continuing to experience a meaningfully better selling environment within the pharma end market, which is in contrast to what was seen in 2022 and the first half of 2023. Our commercial integration strategy between OptimizeRx and Medicx Health is also progressing ahead of schedule. We have dozens of DAAP deals in our pipeline with approximately 50% coming from the direct-to-consumer side of the business, with numerous opportunities in late-stage negotiations. With the addition of Medicx Health capabilities, we stand out as the most scalable platform with both HCP and direct-to-consumer reach. This unique positioning enhances our ability to cross-sell and upsell, unlocking significant value for which we estimate the potential opportunity with existing brands alone to be over $2 billion, with even greater potential for the brands we don't yet support. This favorable environment strengthens our confidence in meeting or exceeding our financial targets in 2024 and beyond. These larger, stickier DAAP deals are strategically targeted making us a more relevant partner with our client base. With our in-house development capabilities and the foundational work over the last several years that's been tailored specifically for pharmaceutical marketers, OPRX now has the ability to materially grow its top line with limited additional overhead. With our Medicx Health acquisition, we are placing extra emphasis to accelerate a highly impactful DTC component. Moving forward, our mission has never been clearer, and we continue to believe that the best is yet to come. With the addition of DAAP to OPRX's omnichannel network, we have a pioneering and foundational AI-directed capability, which removes the mystique of seamlessly integrating point of care in traditional digital media, offering a transparent and holistic solution for pharmaceutical marketing that's able to reach nearly 240 million lives and 2 million HCPs. Our enhanced AI platform, DAAP, coupled with channels outside of the EHR, are driving powerful next-best-action capabilities based on real-world data. As a result, app is now used to power CRM alerts as well as social media, web display, and other mass digital media communication channels, all of which foster greater efficiency and collaboration with our customer sales forces. OPRX is expanding its AI solution work with clients, while others in the space are still trying to figure out how to apply AI. And with that, I'd like to turn the call over to our CFO, Ed Stelmakh, who will walk us through the financials and the details. Ed?

Thanks, Steve, and good afternoon, everyone. The press release was issued with financial results of our first quarter ended March 31, 2024. A copy is available for viewing and may be downloaded from the Investor Relations section of our website. Additional information can be obtained through our forthcoming 10-Q. First quarter revenue came in at $19.7 million, an increase of 51% from the $13 million recognized during the same period in 2023. Gross margin for the quarter increased from 57.2% in the quarter ended March 31, 2023, to 64% in the quarter ended March 31, 2024. Year-on-year gross margin expansion is attributed to higher GAAP-related revenue as well as a favorable channel partner mix. Our operating expenses for the quarter ended March 31, 2024, increased by $2.7 million year-over-year, but included $0.2 million in acquisition-related fees and $0.4 million in severance expenses for the remainder of the increase, largely tied to the Medicx Health acquisition. We had a net loss of $6.9 million or $0.38 per basic and fully diluted share in the 3 months ended March 31, 2024, compared to a net loss of $6.4 million or $0.37 per basic and fully diluted share for the same 3-month period in 2023. On a non-GAAP basis, our net loss for the first quarter of 2024 was $2 million or $0.11 per fully diluted share outstanding compared to a non-GAAP net loss of $1.6 million or $0.09 per fully diluted shares outstanding in the same year-ago period. Our adjusted EBITDA came in at a loss of $0.3 million for the first quarter of 2024 compared to a $2.2 million loss during the same first quarter of 2023. Operating cash flow came in at $2.1 million for the first quarter of 2024, and we ended the quarter with a cash balance of $15.2 million compared to $13.9 million on December 31, 2023. Our debt balance currently stands at $37.8 million. If you recall, to help fund the $84.5 million cash portion of our October Medicx Health acquisition, the company took on $40 million in debt financing and has repaid $2.2 million of principal by the first quarter of 2024. We continue to believe we are well-funded to execute against our operational goals. And now with that, let's turn to our KPIs for the first quarter of 2024. Average revenue for the top 20 commercial manufacturers now stands at $2.5 million, and we work with all top 20 largest pharma companies in the world. Our net revenue retention rate is showing improvement at 116%, up from 86% in Q1 2023. Meanwhile, revenue per FTE came in at $641,000, topping the $605,000 we posted in Q1 2023. We're encouraged by the continuing improvement in our KPIs as we move past external market challenges and return to growth and profitability as a leader in our space. Now with that, I will turn the call back over to the operator for Q&A.

And our first question is from Ryan Daniels with William Blair.

Congrats on the very strong start to the year. Well, maybe one for you. As we look at DAAP, I know it's still a relatively novel platform for you, but I'm curious what type of improvements and maybe ROI metrics you've been able to see as you scale the platform, get more customers, and leverage that data to improve the product?

Thank you, Ryan. The best indication of our progress is the growing number of clients, as they tend to be quite selective. We are constantly learning in this process, and we have a skilled team of data scientists with 2.5 years of experience since we began this initiative. Additionally, we've brought in new team members from the direct-to-consumer side who add their expertise. Our core value proposition is to help clients achieve more through a single partner while maximizing the return on their marketing investments, and it seems to be resonating well. We have also improved our data infrastructure and made investments last year that have enhanced our reporting and analysis capabilities, which are now yielding positive results. When we partner with clients, we engage not only with brand managers but also with executive teams in data and analytics, reporting, and technology. This approach fosters a more robust and comprehensive relationship, which is why we are so enthusiastic about our progress. Steve, is there anything else you would like to add regarding this question?

No, I think you said it. I mean our average, Ryan, as you know, our average ROI has been tracking roughly 10:1 over time. I think if you were to look specifically at DAAP, you're going to see much higher return on investment there. And I think as Will said, our foundational data continues to grow and learn because we've now got a plethora of DAAP deals that have been live for quite a bit of time. And so as the machine learning carries on, they get smarter and smarter and smarter, the algorithms that is. And so as they get smarter, they become more precise and that improves the ROI. So I think we'll cover it nicely, but definitely, a tick up of the 10:1 for sure.

Okay. That's super helpful color. And then maybe, Steve, another one for you. You were pretty specific about the tone of your conversations with pharma manufacturers improving and really being quite different than it was a year or so ago. And I'm curious if you think that relates to just broader end market improvements with more stability in the FDA and with pharma companies in their internal staffing? Or is it really improvements in your offering in DAAP and the power there that's resonating in the market, especially as you've now got a combined HCP DTC product at scale, which is unique in the market? So is it maybe one of those two things? Is it both of them? Just any more color there is I think it's an important data point.

Yes, thanks for the question. I actually think it's both. I think that pharma markets are coming back, meaning that sort of cyclically pharma is now sort of back at the table. They're looking to spend more. They're getting more drugs approved. You're seeing some blockbusters get approved. That sort of obesity market is going to become very frothy here, I think, for everybody following that in the coming months and years. So spend is, I think, back. But in addition to that, I think that while spend is back, it's much more focused. I think during the pandemic and sort of coming out of the pandemic, pharma was in a position where they needed to sort of try anything they could to try to get some leverage and some digital connectivity because they were just laggards in coming to the digital transformation table. Now that they've sort of sorted through that in the last several years, I think they've now picked a couple of the key winners where they want to invest. And from the looks of it, it appears that we're at that table, as you can see, having to dial around expanded investments. So feeling great about that, but I would say it's sort of a balance of both of those things.

Okay. Perfect. And then maybe one for Ed, just on in all three of you. Solid gross margins in the quarter. I'm curious if you could speak to if there's any nuances there you think are unique to the quarter, if we can kind of carry that low 60% gross margin momentum forward throughout the remainder of the year, given what you're seeing in the market and the sales?

Yes. Thanks, Ryan. Yes. So Q1 gross margin is certainly being driven by DAAP success early in the year. As you know, we make more margin when we sell more models. Will it carry through the rest of the year? I mean, certainly, we have some assumptions around DAAP continuing to grow. And if that materializes, there's certainly a potential to be north of 60% throughout the year.

Our next question is from the line of Eric Martinuzzi with Lake Street.

Yes. I wanted to make sure I had a good read on seasonality for 2024. Not looking for a specific number for Q2 revenue, but historically, we would be kind of flat to up slightly Q1 to Q2. Any reason why that would be outside the normal seasonality?

I think you could Oh, go ahead, No, go forward.

Eric, yes, so there should be no reason why that shouldn't continue this year. So as you're modeling numbers for the year, you should absolutely assume the same thing you had last year.

Okay. And then I guess the DAAP deals that we saw in 2023, we had '24, we had 9 in Q1 of '24. Remind me again what qualifies size-wise, and I'm curious to know, not all DAAP deals are equal, but are these million-plus transactions that we're talking about? Is that what it takes to qualify? And then should we expect that same cadence here in Q2 and beyond?

Steve, you want to take that one?

Let me take that one. Yes, no problem. Eric, good to hear your voice. Yes, on an annualized basis, they're still running, on average, about $1 million. I think we're seeing a little to the positive, a little to the negative on those. But ACV-wise, the average is still roughly $1 million, and that's on an annualized basis. So depending on when we close the deal, that will determine how much revenue will pull into the year. But feeling great about the strong growth in DAAP and just sort of where we were compared to where we are now is I think we're all feeling pretty optimistic about it.

To add to that, your question was about what qualifies as a DAAP deal. It really involves a mix of data, analysis, model building, and message delivery. Essentially, that's what makes a deal qualify as a DAAP deal in our context.

Our next question is from the line of David Grossman with Stifel.

I'm curious if you could share your thoughts on the improvement in net revenue retention. Is there a noticeable difference between the DTC and HCP business? Additionally, how might the combination of the two businesses impact the stability and visibility of the revenue stream year-on-year, considering the increased opportunities within the existing base?

Yes. I'll begin and then pass it to Steve. Overall, we appreciated that the Medicx acquisition improved our visibility. We also valued the potential for upsell by integrating them into our DAAP platform for our clients. This approach not only allows for algorithm development but also the addition of more impressions or media. The market and budgets for direct-to-consumer are significantly larger, often three to five times that of healthcare professionals, which positively impacts the potential annual contract value when combining the two. As Steve mentioned, we are actively focused on cross-selling and haven't incorporated much of that into our forecasts yet, so we’re pleased with our progress so far.

Yes, David. You heard us say in the prepared remarks, DAAP, at its core, is a patient-finding technology, meaning finding a brand-eligible patient. And I think that we've already seen the success of finding a brand-eligible patient via their HCP and executing the messaging via the HCP to activate and drive script lift. That's our core at OPRX. What Medicx brings to the table, as you heard Will sort of articulate, is the ability to directly execute messaging to the patient themselves. And then all of that reporting, all of the actions taken, gets fed back into the platform and drives another action. So on the net revenue retention, which was sort of your initial question, how is that going to behave? Well, the platform becomes more subscriptive in nature. Not that we're converting everything to subscriptions, but when programs run, they basically are producing results in more information, which is feeding that baseline core data within the business. And the natural occurrence of that is for clients to renew because the ROI as time goes on improves because of the machine learning that's driven by the platform. So that's, I think, why you're seeing early signs of net revenue retention trickle up, and I think we'll probably continue to see that. We'll see how it goes, but early optimistic signs.

So do you have any sense for where like a target? Is it just too early to really think about what, as a steady-state NRR for the business, given that you're seeing some early improvement, obviously? But just curious whether you have any thoughts on where that shakes out over time.

Yes. We have our internal goals, which we keep private, but we aim to return to the level of hyper retention we previously experienced. If we follow our plan, we should exceed a net revenue retention rate of 120 by the end of the year. Currently, what we have is even better for retention than our earlier, more tactical approach. This new strategy is more comprehensive and integrated within our client organizations, which encourages optimism. We are seeing positive early signs in the first quarter, and the overall year looks promising. This trend is generally beneficial for our business, and we are excited about these initial indicators.

Great. And just one other question, and sorry if I missed this, but did you provide the pro forma growth rate for the quarter?

Do you want to take that?

Sure. Yes. So you'll see the numbers published in our Q tomorrow. So we haven't provided that yet. Once you see the numbers, we can talk about kind of some of the details that go into that.

Our next question is from the line of Constantine Davides with Citizen JMP.

Well, I just wanted to see if you could expand on some of your comments on the commercial infrastructure. Maybe just give us a sense for if the sales force has brought over for Medicx and your legacy sales force are cross-trained, what the size of the infrastructure is. And it sounds like you're pretty constructive on the ability to sort of leverage that in the future years. And again, just wondering if you can give us a little bit more color there.

Yes, I'll hand that over to Steve because he oversees it. But just to say, we've leaned in on investment there because we're seeing the adoption curve happen faster than we anticipated. But Steve, you can give an update on the team and the numbers.

Happy to. Constantine, thanks for the question. We're now up to right around 20 sellers that are actively engaging with pharma, which I think is our largest number. Part of that is via the acquisition of Medicx, and then we've also onboarded several new sellers from the competitive set in the space. We've sort of been very deliberate about recruiting the best talent, all of which we've been able to successfully capture, which is a good sign for the business. So we're feeling pretty good about that. And we've structured it in line with our commercial engine. So we've got folks that are focused on HCP, folks that are focused on DTC, both of which have cross-sell incentives, as you heard Will mention earlier, they're laser-focused on that and showing early signs of successful execution there. And then we have some account management and inside sales capabilities as well just to sort of address top-of-the-funnel and pull-through as we're expanding the pipeline continues to grow. So addressing each step of that pipeline development from inception through execution, that's really where we're focused.

I have a follow-up regarding traditional engagements for DAAP. Could you discuss the frequency and depth of your interactions with your end pharma customer in an adapt structure compared to a more traditional engagement? How often do you communicate, and what is the nature of those conversations? It seems there are more individuals involved based on your earlier comments, and I would appreciate any additional insights on that.

Sure. Yes, happy to take that one. Yes. I mean there are definitely more stakeholders that are involved. Funny enough, the close cycle is roughly the same, believe it or not, but you've got several stakeholders. You have an economic buyer, you've got a strategic buyer, meaning the brand manager, economic buyers always procurement and/or via the agency, and then there's a new buyer at the table, which is the analytics team. The benefit, I think, of having that analytics team at the table, which is sort of a follow-on to Ryan's question around ROI, is that the metrics that are governing the ROI calculation and what success looks like are decided early and often by that team concomitantly with our analytics team. And so we know exactly how we are driving and what we're driving to, to be successful. And that gives our platform an ability to make adjustments on the fly and do things that optimize every engagement, making sure that everything is optimized perfectly to drive a good result by the end of the campaign. So it's great to have them as a sort of partner at the table. And it also makes things much stickier. I think once you're sort of implemented with an analytics team and the marketing team and the agency, et cetera, and everyone's part of the workflow, renewability is better. And again, the net revenue retention continues to tick up. I think that's sort of a byproduct of the stakeholder engagement.

Our next question comes from the line of Stephanie Davis with SVB.

I do want to ask, so the revenue from your top 10, that mix is improving quite a bit. But it is still below what we've seen prior to last year. So thinking about that, is there a path to recovery? Or is there naturally going to be some SKU going forward, just either due to the DTC mix or prior SKU due to the pandemic?

Yes, I don't think it's pandemic-related. It didn't really have a material impact on our business during those years. However, the combination of the two brand sets, medics and OPRX, is showing good improvement. If the DAAP cross-sells work, that should accelerate nicely. From the perspective of investors and analysts, it's important to keep an eye on the success of cross-selling. Overall, we are pleased to be involved with all of them and are operating well with retention at a satisfactory level. As Steve mentioned, the team is training effectively on cross-selling and is actively engaged in the market with it.

Helpful. And then I look at the pipeline, you did highlight a lot of DAAP deals that are making up most of the pipeline. Is there anything unique in that? Is that a quicker negotiation cycle? Is that something where the revenues hit a little quicker? Like how should we think about compared to kind of your legacy book of business?

Sure. Steve, do you want to grab that one?

Yes, happy to. Stephanie, good to hear your voice. Look, I think that there are two things that I would sort of consider. So average deal size in that DAAP range is going to be significantly larger than our normal deal size, which you know. So we've already shared the ACV around that. In addition to that, I think the sales cycle is pretty much approaching what our normal sales cycle would be. And I think that's largely because we're in a scale place right now with that as opposed to just sort of a kind of launch scale, which we were 12 months ago. And then the other thing that I would sort of submit to you is, and this is kind of based on your previous question as well, is that we're not just seeing DAAP gain traction and be sticky in the top 10. We're seeing it gain traction across the spectrum of revenue tiers in our client base. And that is really something that we're excited about, which is to say that in the mid-tier and the small accounts, we're seeing spend levels that are as large on a deal basis as some of the major manufacturers. And we think right now that that's because major manufacturers have capabilities that they assume are taking care of several of the things that they might be looking for out in the marketplace. They've got some of those things in-house, whereas mid-tier and smaller accounts just simply don't. And so it's much more cost-effective for them from both an investment and a time perspective to find a solution that can cover several of the things that DAAP is bringing to the table. So more to come on that, but I just wanted to give you a sense of the spread of DAAP and based on your previous question as well, too.

Okay. Well, those two answers in mind, I want to follow up then on the NRR question. It sounds like there's a lot of new sales of new products. Is it safe to think that these big improvements you're seeing in NRR is more from new sales of new products and improvements in attrition versus new sales of legacy or core products?

I'll start with that. One of the things that's really encouraging is that when we have a more significant tactical engagement with clients, who are all aware of or are using some form of DAAP program, we are at the point where they are considering larger programs to convert to DAAP for better efficiency. There hasn’t been a decline in pricing; in fact, the size of the engagement has increased significantly. It’s early days, but moving from '24 to '33 in the first three months shows promise. I believe that by mid-year, we'll see how many we finalize and how it affects all our KPIs, but we anticipate a positive outcome. Our legacy business is not suffering; instead, it is being enhanced, becoming more relevant and engaging. Kudos to the team for achieving this transition to a different type of solution, which can often be challenging, as clients can be fixed in their mindset. However, in this case, we are evolving into something more meaningful and relevant, which is excellent.

Our final question is from the line of William Wood with B. Riley Securities.

So it looks like that net aesthetics is, you said earlier, that was progressing ahead of expectations on the late-stage negotiations are still going on. So I'm just kind of curious if these have already been included in the guidance for this year or if these will be extra to that? And when we think all of this should be closing out in these negotiations should be starting to solidify.

Thank you for the question. When acquiring a company, you only truly understand its dynamics after the purchase. Therefore, we approached our 2024 guidance with caution and did not factor in any potential cross-selling. If we see this occur sooner than expected, it would positively impact both our guidance and our clients. I believe we could see this progress in the second half of the year, as midyear is typically when clients reassess and adjust their allocations, similar to what we observed in the latter half of last year. We anticipate a similar boost this time, specifically regarding the inclusion of DTC. While we should not expect much from the first half, the developments in our pipeline during this period have been very encouraging, and the team is performing exceptionally well.

Got it. That's appreciated. It's very helpful. I just want to make sure I'm thinking about this correctly. It seems there is some seasonality between the fourth and first quarters. When looking at a quarter-over-quarter basis rather than year-over-year, it appears there was a slight decline across the board in revenues, gross revenues, adjusted EBITDA, and so on. However, DAAP increased, and now you have 9 DAAP. As we consider this going forward, does this mean that the transition from the fourth quarter to the first quarter wasn’t as significant? I know you came in strong, so I’m trying to understand how to properly gauge the DAAP and revenue growth throughout the year.

Yes, sure. And I'll hand you over to Andy for the seasonality numbers. But 23% to 24% less than 20% of the business is DAAP. So you're still going to see that seasonal drop from Q4 to Q1 that we've seen historically. But as we scale DAAP and you get closer to 50% a year or more of your revenue, you'll always have a bit of a reset, but it should start to be better over time because you've got active programs rolling forward. You've got algorithms being updated. And there's a sequence to Q1 when we close those deals, really, the first part of that is getting the model built. So you won't see a big pop immediately. You really get that revenue designing the algorithm and launching programs and then it carries through. So seasonality will all exist in this business, but it should get better as that becomes a higher percentage of our revenue.

William, it's Andy. I hope you're doing well. So just from a first half or second half standpoint, typically, our first half is not going to be more than 40% of our overall revenue in the year. So call it the 35% to 40% range, and then the back half would be the remainder. So I hope that gives some context, obviously, as we scale up DAAP, we'll give better insight into how the seasonality and cadence might change, but that's kind of where it's at right now.

Great. Thanks, operator, and thank you, everyone, for joining us today. We trust you share our enthusiasm as we continue to build positive momentum. As we embark on our financial and operational journey, we're pleased to be progressing on solid ground. Our collaboration with pharma manufacturers to reach healthcare professionals and patients has seen really, really nice growth, fueled by our innovative AI models. This advancement has helped us address and overcome many past challenges. Today, we proudly offer comprehensive solutions that integrate various components into agile, powerful strategies. These strategies effectively tackle crucial issues such as brand awareness, education, affordability, and the recruitment of hard-to-find patients. These are the daily challenges our clients, doctors, and patients face in the current healthcare environment. And we are very excited to be part of the solution. Our dedication to supporting doctors and patients and aligning on quality care is the driving force behind our team. We're looking forward to connecting with many of you at the numerous upcoming investor conferences we'll attend before our next earnings call. Wishing you a great rest of the day. Thanks.

Thank you, sir. Before we conclude today's earnings call, I would like to provide the company's safe harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today's earnings call may contain forward-looking statements within the definition of Section 27A, the Securities Act of 1933, as amended, and Section 21 of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible, and seeking and similar expressions identify forward-looking statements. They may speak only to the date that such statements are made. Such forward-looking statements in the call include statements regarding estimation of total addressable market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments, growth opportunities, acquisitions, and upcoming announcements. They also include the management's expectations for the rest of the year and the adoption of the company's dynamic audience actuation platform. The company undertakes no obligation to publicly update or revise any forward-looking statements whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying these forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effects of government regulation, competition, and other material risks. Risks and uncertainties that could affect business and financial results and to which forward-looking statements are subject are included in the company's annual report on Form 10-K for the year ended December 31, 2023. This Form 10-K is available on the company's website and on the SEC website at sec.gov. Before we end today's earnings call, I would like to remind everyone that this call will be available for replay via webcast only starting later this evening, running through for a year. Please refer to today's press release for replay instructions available via the company's website at www.optimizerx.com. Thank you for joining us today. This concludes today's earnings call. You may now disconnect your lines.